Program
Megestrol Acetate
Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.
Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 77 open or running | phase 4since Nov 15, 2025 | Dec 25, 2024 | Dec 31, 2026phase 4 · NCT07243379 |
| Bristol-Myers Squibb | 30 open or running | phase 4since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Par Health | 30 open or running | phase 3since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Keenova Therapeutics | 20 open or running | phase 2since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Rottapharm Spain | 20 open or running | phase 3since Jul 17, 2007 | Jul 17, 2007 | none ahead |
| TTY Biopharm | 10 open or running | phase 2since Jul 25, 2016 | Jul 25, 2016 | none ahead |
Also a collaborator on its studies: quintiles-inc, covance, sfbc-anapharm and pra-health-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 2, 1999.
- Nov 2, 1999Phase 3 study in AnorexiaBristol-Myers Squibb · NCT00002067 · United States
- Jul 17, 2007Rottapharm Spain's first study: phase 3 study in DementiaNew to Rottapharm SpainRottapharm Spain · NCT00503516 · 39 enrolled · Spain
- Jul 26, 2007Phase 2 study in Pulmonary Disease, Chronic ObstructiveRottapharm Spain · NCT00507949 · 40 enrolled · Spain
- Mar 11, 2008Keenova Therapeutics's first study: phase 1 study in PharmacokineticsNew to Keenova TherapeuticsKeenova Therapeutics · NCT00638079 · 24 enrolled · Canada
- Mar 11, 2008Par Health's first studies: 2 phase 3 studies in AnorexiaNew to Par HealthPar Health · NCT00637806, NCT00637728
- Mar 11, 2008Phase 2 study in HIV InfectionsKeenova Therapeutics · NCT00637572 · 63 enrolled · United States, India, South Africa
- Mar 11, 2008Phase 1 study in Renal InsufficiencyPar Health · NCT00637403 · 7 enrolled · United States
- Jul 25, 2016TTY Biopharm's first study: phase 2 study in Head and Neck NeoplasmsNew to TTY BiopharmTTY Biopharm · NCT02980653 · 105 enrolled · Taiwan
- Dec 25, 2024Changchun GeneScience Pharmaceutical's first study: phase 3 study in Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk FactorsNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06772428 · 96 planned · China
- Feb 11, 2025No phase study in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line TreatmentChangchun GeneScience Pharmaceutical · NCT06830018 · 76 planned · China
- Apr 29, 20252 phase 3 studiesChangchun GeneScience Pharmaceutical · NCT06961201, NCT06961188
- Aug 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663 · 134 planned · China
- Nov 15, 2025Phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379 · 495 planned · China
- Jan 4, 2026Phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037 · 68 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaChangchun GeneScience Pharmaceutical · NCT07243379
- Dec 31, 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaChangchun GeneScience Pharmaceutical · NCT06961201
- Jun 30, 2027Primary completion: phase 3 study in CachexiaChangchun GeneScience Pharmaceutical · NCT07356037
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungChangchun GeneScience Pharmaceutical · NCT07150663
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levonorgestrelrule | Bayer | phase 4 | 56 |
| drospirenonerule | estetra | phase 4 | 20 |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 11 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07356037Cachexia · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 68 |
| NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · China | 4 | Recruiting | Changchun GeneScience Pharmaceutical | Dec 31, 2026 | 495 |
| NCT07150663Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 134 |
| NCT06961201Small Cell Lung Carcinoma · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Dec 31, 2026 | 94 |
| NCT06961188Neoplasm Metastasis · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 174 |
| NCT06830018Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment · China | – | Recruiting | Changchun GeneScience Pharmaceutical | Jan 2026 | 76 |
| NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors · China | 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical | Jun 30, 2027 | 96 |
| NCT02980653Head and Neck Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | Aug 2017 | 105 |
| NCT00638079Pharmacokinetics · Canada | 1 | Completed | Keenova Therapeutics | Jul 2006 | 24 |
| NCT00637806Anorexia · United States | 3 | Terminated | Par Health | Sep 2006 | 4 |
| NCT00637728Anorexia · United States | 3 | Terminated | Par Health | Sep 2006 | 5 |
| NCT00637572HIV Infections · United States, India, South Africa | 2 | Completed | Keenova Therapeutics | Jun 2005 | 63 |
| NCT00637403Renal Insufficiency · United States | 1 | Terminated | Par Health | May 2006 | 7 |
| NCT00507949Pulmonary Disease, Chronic Obstructive · Spain | 2 | Completed | Rottapharm Spain | Apr 2009 | 40 |
| NCT00503516Dementia · Spain | 3 | Terminated | Rottapharm Spain | Dec 2009 | 39 |
| NCT00002345Anorexia · United States | 4 | Completed | Bristol-Myers Squibb | 40 | |
| NCT00002300Anorexia · United States | 2 | Completed | Bristol-Myers Squibb | ||
| NCT00002067Anorexia · United States | 3 | Completed | Bristol-Myers Squibb |
How it is read
Names in the registry
- “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
- “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
- “Megestrol acetate”, 5 entries
- “Nanocrystalline Megestrol Acetate”, 2 entries
- “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries
Conditions, from the studies’ own filings
- Anorexia, 5 studies
- Cachexia, 2 studies
- Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.